This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
-- Fifth Annual OneMedForum San Francisco Conference to Feature Emerging Healthcare and Life Science Companies --TSX Venture Exchange: NVC
Jan. 4, 2012 /PRNewswire/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today announced that the company will present at the OneMedForum San Francisco 2012 Finance Conference on
January 10, 2012 at
12 pm PST. The conference will be held at the Sir Francis Drake Hotel in
San Francisco. Neovasc management will provide an overview of recent company developments and plans for 2012.
Alexei Marko commented, "This is an exciting time for the company, as our Neovasc Reducer™ for the treatment of refractory angina recently received CE mark approval in
Europe and our biological tissue business continues to show steady growth. We also are continuing to enroll patients in the COSIRA study and are now in the process of initiating clinical registries in
Europe and elsewhere, which will soon begin enrolling Reducer patients. We also are making good progress in the development of our novel Tiara™ technology for the transcatheter treatment of mitral valve disease. We look forward to discussing our plans for 2012 with the many life sciences investors who will be in
San Francisco next week to kick off the new business year."
An updated corporate presentation that includes the material presented during the OneMedForum presentation will be posted on the Neovasc website at the time of the session on
January 10, 2012, at
About Neovasc Inc. Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves. For more information, visit:
About OneMedForum OneMedForum is a financial conference that includes industry-focused panel sessions, numerous networking opportunities and presentations by some of the most promising emerging medical device, biotech and health information companies. OneMedForum San Francisco 2012 runs concurrently with the J.P. Morgan Healthcare Conference, providing efficient access to the companies shaping the future of the rapidly changing healthcare landscape. For more information, visit:
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.